ClinicalTrials.gg
WithdrawnNCT06483802Updated Nov 28, 2025

A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia

A Phase 1 interventional study of ASP2016 and Prednisolone in Friedreich Ataxia and Cardiomyopathy, sponsored by Astellas Gene Therapies. Withdrawn. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Corporate decision to withdraw the trial at this time.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Friedreich Ataxia is a rare condition that causes damage to the nervous system and muscles. People with Friedreich Ataxia have difficulty walking, lose sensation in their arms and legs, and have slurred speech. It can also affect the heart and many people with Friedrich Ataxia develop serious heart problems. Friedreich Ataxia is a genetic condition which means a faulty gene is passed down through families. This type of gene therapy treats a genetic condition by providing a healthy copy of the gene.

At the time this study started, there was no approved treatment for heart problems in people with Friedreich Ataxia.

In this study, ASP2016 is being tested in humans for the first time. The people taking part are adults with Friedreich Ataxia who have heart problems.

The main aims of the study are to check the safety of ASP2016 and how people cope with (tolerate) ASP2016. ASP2016 is given as a slow injection into a vein. This is called an infusion. People will also take tablets of a medicine called prednisolone. This is taken to stop the immune system interfering with ASP2016.

Each person in the study will be given 1 single infusion of ASP2016. Different small groups will receive lower or higher doses of ASP2016. Each person will stay overnight in the clinic for at least 1 night after their infusion.

For the first few months, people will visit the clinic regularly. There may be the option of home visits by a study nurse at some visits. At the 6-month and 12-month visits extra tests, procedures, and scans will be done. One of these is an ECHO (echocardiogram) scan. This is like an ultrasound scan for the heart. Another is an endomyocardial biopsy. A tiny piece of their heart tissue is removed (biopsy). A flexible hollow tube (catheter) goes into the blood vessels up to the heart. Then, a small device on the end of the catheter takes a tiny piece of heart tissue (about the size of a pencil tip). Another is a cardiac MRI. This takes pictures of the inside of the heart using a powerful magnet. Another is a cardiopulmonary exercise test (CPET). This involves moving a specially designed set of bicycle pedals using hands and arms. This will check how the lungs, heart and muscles are affected during exercise.

After the 12-month visit, people will visit the clinic every few months for up to a few years.

02

Conditions studied

  • Friedreich Ataxia
  • Cardiomyopathy

Keywords

  • ASP2016
  • Friedreich Ataxia Cardiomyopathy
  • Frataxin
  • Friedreichs Ataxia
  • Heart
  • Gene Therapy
03

In context

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Lead sponsor

Astellas Gene Therapies is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

First submitted after Astellas Gene Therapies became part of Astellas Pharma Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has both a clinical diagnosis of Friedreich ataxia (FA) and a documented history of genetic diagnosis of FA with either a guanine-adenine-adenine (GAA) trinucleotide repeat (TNR) expansion in intron 1 of both gene for frataxin (FXN) alleles or a GAA TNR expansion of intron 1 of one FXN allele and a pathogenic variant in the other FXN allele.
  • Participant has a resting ≥ 40% and \< 55% as measured at screening by ECHO.
  • Participant has a range of 17.0 to 30.0 kg/m2.
  • Participant agrees not to begin omaveloxolone treatment during the 52-week period after receiving study intervention.
  • Participants on omaveloxolone, who opt to discontinue omaveloxolone, may enroll if they stop omaveloxolone for 3 weeks and pass study screening, including LFTs.
  • Participants on omaveloxolone, who opt to stay on omaveloxolone will need to have been on it for a minimum of 3 months, with LFTs that pass diagnostic assessments exclusion criteria at screening and prior to dosing with ASP2016. Prior elevation(s) in /ALT associated with omaveloxolone use must be discussed with the sponsor medical monitor. If there is a liver function test (LFT) elevation after treatment, participant agrees to stop omaveloxolone treatment until 52 weeks.
  • Participants on omaveloxolone will need to discontinue strong or moderate cytochrome P450 3A4 () inducers and inhibitors.
  • Woman of Child Bearing Potential () on omaveloxolone must use a nonhormonal, highly effective methods of (e.g., nonhormonal intrauterine device system), as omaveloxolone may interfere with hormonal methods of contraception.

Exclusion criteria

Exclusion Criteria:

  • Participant has late-onset FA, defined as symptom onset after the age of 25 years.
  • Participant is unable to complete cardiopulmonary exercise testing (CPET) procedure.
  • Participant has a to endomyocardial or cardiac catheterization.
  • Participant has a contraindication to cardiac magnetic resonance imaging (CMRI) with contrast, including to gadolinium contrast agent, cardiac pacemaker or implantable cardiac defibrillator.
  • Participant has an elevated titer of anti-AAV8 total antibodies, as determined by central testing.
  • Participant has significant fibrosis on CMRI, defined as late gadolinium enhancement of > 15% left ventricular myocardial mass.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ASP2016

    Participants will receive a single dose of ASP2016. Participants will also receive daily prednisolone beginning 1 day prior to ASP2016 dose and for at least 16 weeks after ASP2016 dose, in order to suppress the immune response to ASP2016.

    Genetic: ASP2016 · Drug: Prednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    A TEAE is defined as an AE observed after starting administration of the study intervention. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Note: an AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

    Time frame: Up to month 60

  2. Number of Participants with Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other medically important events.

    Time frame: Up to month 60

  3. Number of participants with laboratory value abnormalities and/or AEs

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to month 60

  4. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to month 60

  5. Number of participants with physical exam value abnormalities and/or AEs

    Number of participants with potentially clinically significant physical exam values.

    Time frame: Up to month 60

Secondary outcomes

  1. Change from baseline of frataxin protein level in cardiac tissue

    Frataxin protein level in cardiac tissue will be recorded from endomyocardial biopsies collected by cardiac catheterization.

    Time frame: Baseline, week 24 and week 52

  2. Change from baseline of peak rate of oxygen consumption (VO2peak)

    VO2peak will be measured by upper extremity cardiopulmonary exercise testing (CPET).

    Time frame: Baseline, week 24 and week 52

  3. Change from baseline of ventilatory anaerobic threshold (AT)

    AT will be measured by upper extremity CPET.

    Time frame: Baseline, week 24 and week 52

  4. Change from baseline of ventilation (VE)/volume of exhaled carbon dioxide (VCO2) slope

    VE/VCO2 slope will be measured by upper extremity CPET.

    Time frame: Baseline, week 24 and week 52

  5. Change from baseline of left ventricular ejection fraction (LVEF)

    LVEF will be measured by echocardiogram (ECHO).

    Time frame: Baseline, week 24 and week 52

  6. Change from baseline of left ventricular mass index (LVMI)

    LVMI will be measured by ECHO.

    Time frame: Baseline, week 24 and week 52

  7. Change from baseline of longitudinal cardiac strain

    Longitudinal cardiac strain will be measured by ECHO.

    Time frame: Baseline, week 24 and week 52

  8. Change from baseline of vector copy number (VCN)

    VCN will be recorded from endomyocardial biopsies collected by cardiac catheterization.

    Time frame: Baseline, week 24 and week 52

  9. Change from baseline of total antibody (TAb) to adeno-associated virus 8 (AAV8)

    TAb to AAV8 will be recorded from serum samples collected.

    Time frame: Baseline and up to week 52

  10. Change from baseline of neutralizing antibody (NAb) to AAV8

    NAb to AAV8 will be recorded from serum samples collected.

    Time frame: Baseline and up to week 52

  11. Change from baseline of TAb to frataxin

    TAb to frataxin will be recorded from serum samples collected.

    Time frame: Baseline and up to week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Hendrickx N, Mentre F, Hamdan A, Karlsson MO, Hooker AC, Traschutz A, Gagnon C, Schule R, Synofzik M, Comets E; ARCA Study Group, EVIDENCE-RND consortium. Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score. BMC Med Res Methodol. 2025 Jul 30;25(1):179. doi: 10.1186/s12874-025-02626-x. PubMed 40739200 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Oct 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 3, 2024
StartActual
Nov 8, 2024
Primary completionActual
Oct 22, 2025
CompletionActual
Oct 22, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06483802
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Nov 8, 2024
Primary completion
Oct 22, 2025
Completion
Oct 22, 2025
Last update
Nov 28, 2025

Study contacts

Global Medical Lead
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisolone

Start the discussion